Posts for Ticker ‘MAPP’

Top Analyst Upgrades (BBBY, MAPP, ISLE, OMX, PCZ, RF, SPLS, SYMC)

These are the top pre-market analyst upgrades and positive research calls we have seen from Wall Street firms this Wednesday morning:

Bed Bath & Beyond (BBBY) Started as Outperform at Oppenheimer.
MAP Pharmaceuticals (MAPP) Raised to Buy at Deutsche Bank.
Isle of Capri (ISLE) Raised to Outperform at oppenheimer.
OfficeMax (OMX) Started as Outperform at Oppenheimer.
Petro-Canada (PCZ) Raised to Overweight at Barclays.
Regions Financial (RF) Raised to Buy at Deutsche Bank.
Staples (SPLS) Started as Outperform at Oppenheimer.
Symantec (SYMC) Raised to Outperform at Morgan Keegan.

JON C. OGG

Posted on: May 27, 2009 – 6:58 am in Analyst Calls, , , , , , , ,

George Soros Top Equity Holdings (AAPL, AUXL, BFLY, CBI, CMG, CRUS, COV, MAPP, POT, SVNT)

This week we got to see critical SEC filings showing holdings of many key and influential investors.  Included in these filings were billionaire George Soros, a billionaire whom is loved by some and much less ‘well thought of’ by others over his currency trading history of over his MoveOn.org attempts.  Either way, investors still watch Soros.  These are the holdings of Soros Fund Management LLC as of December 31, 2007.  These were listed as the top holdings and are not at all his entire positions.  Soros Fund Management LLC was listed as having some $2.269 Billion in the total filing, and these positions here only equate to $360+ million, so there are many more positions.  As with all of these holdings, these positions may have changed or been eliminated as of the dates noted.  Here is a summary of his larger positions with a dollar amount provided by Soros as filer and a share count:

  • Apple Inc. (NASDAQ: AAPL)   $32,000,000;  161,550 shares
  • Auxilium Pharma (NASDAQ: AUXL)   $36,473,000;  1,216,180 shares
  • Bluefly Inc. (NASDAQ: BFLY)   $36,451,000;  48,601,156 shares… an old favorite of his…
  • Chicago Bridge & Iron Co. (NYSE: CBI)   $29,743,000;  492,100 shares
  • Chipotle Mexican Grill, Inc. (NYSE: CMG)  $32,404,000;  220,332 shares
  • Cirrus Logic Inc. (NASDAQ: CRUS)   $24,376,000;  4,616,666 shares
  • Covidien, Ltd. (NYSE: COV)   $32,194,000;  726,900 shares
  • MAP Pharmaceuticals (NASDAQ: MAPP)   $71,374,000;  4,076,169
  • Potash Corp. (NYSE: POT)   $37,933,000;  263,500 shares
  • Savient Pharmaceuticals (NASDAQ: SVNT)   $25,002,000;  1,088,461 shares

As Soros himself says …."Contrary to the tenets of market fundamentalism, financial markets do not tend towards equilibrium; they are crisis prone."   

Other billionaires and their holdings filed this week:
Bill Gates
Carl Icahn
Warren Buffett

Jon C. Ogg
February 16, 2008

Posted on: February 16, 2008 – 9:17 am in Insider Activity, , , , , , , , , ,

IPO Filing: MAP Pharmaceuticals, the New Inhaler

A new inhaled-molecule company named MAP Pharmaceuticals, Inc. has filed for an IPO.  Underwriters are listed as Merrill lynch, Morgan Stanley, and Deutsche Bank.  It has a proposed stock ticker of "MAPP" on NASDAQ.

Here is the self-description of the company: We use our proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. We have several proprietary product candidates in clinical development which address large market opportunities, including our two most advanced product candidates, Unit Dose Budesonide, or UDB, for pediatric asthma and MAP0004 for migraine. We have announced positive results from Phase 2 clinical studies of UDB and MAP0004, and anticipate initiating Phase 3 clinical programs for both product candidates in early 2008. We hold worldwide commercialization rights for each of our product candidates, and intend to market UDB and MAP0004 in the United States through our own focused sales force targeting pediatricians and neurologists.

The company also has MAP0001 as a proprietary formulation of insulin for the treatment of Type 1 and Type 2 diabetes via pulmonary delivery using our Tempo inhaler, whichh was active in Phase Ia clinical studies.  The company is in development stages, so has no real revenues to speak of.  When you look through the 5% stockholder list you’ll see some familiar names: Perseus-Soros; Pequot; Brookside.  If the company’s inhaled smaller molecules are as promising as they sound, this will be a company to watch.

Jon C. Ogg
June 18, 2007

Posted on: June 18, 2007 – 8:37 am in Biotech, IPOs,